Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:

Ambarella Inc (NASDAQ:AMBA)’s shares picked up 7.04%, and closed at $67.49, hitting new 52-week high of $68.50.

Ambarella, Inc. (AMBA), a leading developer of low-power, HD video compression and image processing semiconductors, declared financial results for its fiscal fourth quarter and year ended January 31, 2015.

Proceed for the fourth quarter of fiscal 2015 was $64.7 million, up 61.9% from $40.0 million in the same period in fiscal 2014. For the fiscal year ended January 31, 2015, proceed was $218.3 million, up 38.5% from $157.6 million for the year ending January 31, 2014.

Gross margin under U.S. generally accepted accounting principles (GAAP) for the fourth quarter of fiscal 2015 was 64.1%, contrast with 64.0% for the same period in fiscal 2014. For the year ended January 31, 2015, GAAP gross margin was 63.7%, contrast with 63.4% for the year ended January 31, 2014.

GAAP net revenue for the fourth quarter of fiscal 2015 was $17.7 million, or $0.53 per diluted ordinary share, contrast with GAAP net revenue of $5.5 million, or $0.18 per diluted ordinary share, for the same period in fiscal 2014. GAAP net revenue for the year ended January 31, 2015 was $50.6 million, or $1.57 per diluted ordinary share. This compares with GAAP net revenue of $25.7 million, or $0.85 per diluted ordinary share, for the year ended January 31, 2014.

Ambarella reports gross margin, net revenue and earnings per share in accordance with GAAP and, additionally, on a non-GAAP basis. Non-GAAP financial information excludes the influence of stock-based compensation and the associated tax influence. A reconciliation of the GAAP to non-GAAP gross margin, net revenue and earnings per share numbers, in addition to a description of the items excluded from the non-GAAP calculations, is comprised of in the financial statements portion of this press release.

Ambarella, Inc. (AMBA), is a leading developer of low-power, high-definition (HD) and Ultra HD video compression and image processing solutions. The corporation’s products are used in a variety of professional and consumer applications counting security IP-cameras, sports cameras, wearable cameras, flying cameras and automotive video processing solutions. Ambarella compression chips are also used in broadcasting TV programs worldwide.

Arena Pharmaceuticals, Inc (NASDAQ:ARNA), raised 6.93%, and closed at $4.32.

Arena Pharmaceuticals, Inc. (ARNA), offered a corporate update and stated financial results for the fourth quarter and full year ended December 31, 2014.

Arena Financial Update:

Raised about $100.7 million in net proceeds in the first quarter of 2015 through the sale of 21.0 million shares of ordinary stock at a price to the underwriters of $4.8139 per share.

Fourth Quarter 2014 Financial Results:

• Proceeds totaled $9.2 million, counting $3.8 million in net product sales of BELVIQ, of which $3.2 million represented 31.5% of Eisai’s net product sales and $0.6 million related to redemptions of the 15-day free voucher and product samples.
• Research and development expenses totaled $27.8 million.
• General and administrative expenses totaled $8.9 million.
• Net loss was $32.1 million, or $0.15 per share.
• At December 31, 2014, cash and cash equivalents totaled $163.2 million, not counting net proceeds of $100.7 million from the issuance of ordinary stock in the first quarter of 2015.
• At December 31, 2014, about 220.3 million shares of ordinary stock were outstanding, not counting 21.0 million shares of ordinary stock issued in the financing in the first quarter of 2015.

Arena Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The corporation offers BELVIQ, a drug used to treat chronic weight administration in adults.

VIVUS, Inc (NASDAQ:VVUS), enhanced 6.81%, and closed at $2.98. The company holds the market capitalization of 291.79M. The stock return on equity value is -73.60%, while return on assets value is -20.90%, in response to its return on investment value of - 16.10%. Its 200-day moving average declined -21.97%, and the stock moved above 50-day moving average of 5.86%. The mean recommendation of analysts for this stock is 3.30.(where 1=Buy, 5=Sale).

ZIOPHARM Oncology Inc (NASDAQ:ZIOP), rose 6.81%, and closed at $13.34, hitting new 52-week high of $13.48.

ZIOPHARM Oncology, Inc. (ZIOP), declared financial results for the fourth quarter and full year ended December 31, 2014, and offered an update on the corporation’s recent activities.

Recent and Forthcoming Corporate Highlights:

In January of 2015, ZIOPHARM and its partner, Intrexon Corporation, reached an exclusive license contract with The University of Texas MD Anderson Cancer Center for programs and associated technologies related to the development of non-viral adoptive cellular therapies, counting CAR T, TCR and NK cell-based therapies. When combined with Intrexon’s technology suite and ZIOPHARM’s further clinical validation of the RheoSwitch Therapeutic System(R), the resulting proprietary methods and technologies may assist realize the promise of genetically modified immune cells by tightly controlling expansion and activation in the body, thereby minimizing off-tissue effects and toxicity while maximizing therapeutic efficacy. As importantly, the use of a non-viral gene integration platform and cell technologies with both point of care and off the shelf applications advance the potential for addressing cancer’s global scale. Together, these programs and technologies are designed to bypass the cost, time and complexity of development associated with existing CAR T and other cell-based therapies, with applicability in both hematologic and solid tumor malignancies.

Fourth-Quarter 2014 Financial Results:

• Net loss for the fourth quarter of 2014 was $10.4 million, or $(0.09) per share, contrast to a net loss of $8.9 million, or $(0.09) per share, for the fourth quarter of 2013. Comprised of in the loss for the fourth quarter of 2014 was a non-cash gain of $194 thousand contrast to a non-cash loss of $1.8 million for the fourth quarter of 2013. The non-cash gain/loss is related to the change in the fair value of the Corporation’s outstanding liability-classified warrants.
• Research and development expenses were $8.1 million for the fourth quarter of 2014 contrast to $2.7 million for the fourth quarter of 2013. The raise of $5.4 million in research and development expenses is primarily attributable to our synthetic biology programs, which have recently expanded.
• General and administrative expenses were $2.9 million for the fourth quarter of 2014 contrast to $4.2 million for the fourth quarter of 2013.
• During the fourth quarter of 2014, the Corporation issued 1,755,845 shares of its ordinary stock upon the exercise of outstanding warrants resulting in aggregate proceeds to the Corporation of about $6.9 million.

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology corporation employing novel gene expression, control and cell technologies to deliver safer, more effective and scalable cell-based therapies for the treatment of cancer.